An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency
Open Access
- 1 June 2004
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 9 (6) , 786-803
- https://doi.org/10.1016/j.ymthe.2004.03.017
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genesCancer Gene Therapy, 2002
- Oncolytic biotherapy: a novel therapeutic platformThe Lancet Oncology, 2002
- Inhibition of TRAIL-Induced Apoptosis and Forced Internalization of TRAIL Receptor 1 by Adenovirus ProteinsJournal of Virology, 2001
- E1B 19K Blocks Bax Oligomerization and Tumor Necrosis Factor Alpha-Mediated ApoptosisJournal of Virology, 2001
- The Hallmarks of CancerCell, 2000
- Interaction of E1B 19K with Bax is required to block Bax-induced loss of mitochondrial membrane potential and apoptosisOncogene, 1998
- Control of Apoptosis by Human Adenovirus GenesSeminars in Virology, 1998
- Cancer Cell CyclesScience, 1996
- The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein.Genes & Development, 1996
- Adenovirus 2 lp+ locus codes for a 19 kd tumor antigen that plays an essential role in cell transformationCell, 1983